OTCPK:IOBC.F

Stock Analysis Report

Executive Summary

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally.

Snowflake

Fundamentals

Limited growth with imperfect balance sheet.

Risks

  • Ion Beam Applications is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Ion Beam Applications's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:IOBC.F

0.8%

US Medical Equipment

1.1%

US Market


1 Year Return

-24.8%

OTCPK:IOBC.F

9.6%

US Medical Equipment

2.1%

US Market

IOBC.F underperformed the Medical Equipment industry which returned 9.1% over the past year.

IOBC.F underperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

IOBC.FIndustryMarket
7 Day0%0.8%1.1%
30 Day-2.5%0.2%3.7%
90 Day9.5%2.7%2.3%
1 Year-24.8%-24.8%10.5%9.6%4.4%2.1%
3 Year-62.9%-62.9%69.5%64.3%47.0%37.4%
5 Year2.6%2.6%132.5%105.9%61.6%43.8%

Price Volatility Vs. Market

How volatile is Ion Beam Applications's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Ion Beam Applications undervalued based on future cash flows and its price relative to the stock market?

4.57x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Ion Beam Applications's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Ion Beam Applications's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Ion Beam Applications is loss making, we can't compare its value to the US Medical Equipment industry average.

Ion Beam Applications is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Ion Beam Applications, we can't assess if its growth is good value.


Price Based on Value of Assets

Ion Beam Applications is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Ion Beam Applications expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

6.6%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Ion Beam Applications's revenue is expected to grow by 6.6% yearly, however this is not considered high growth (20% yearly).

Ion Beam Applications is expected to become profitable in the next 1-3 years, this is considered high growth.

Ion Beam Applications's revenue growth is positive but not above the United States of America market average.

Unable to compare Ion Beam Applications's earnings growth to the United States of America market average as no estimate data is available.

Ion Beam Applications is expected to become profitable in the next 1-3 years, this is considered above the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Ion Beam Applications will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Ion Beam Applications performed over the past 5 years?

-44.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Ion Beam Applications does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Ion Beam Applications's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Ion Beam Applications's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Ion Beam Applications has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Ion Beam Applications has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Ion Beam Applications improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Ion Beam Applications's financial position?


Financial Position Analysis

Ion Beam Applications is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Ion Beam Applications's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Ion Beam Applications's level of debt (66.1%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (37.6% vs 66.1% today).

Debt is not well covered by operating cash flow (17.5%, less than 20% of total debt).

Unable to confirm if the interest payments on Ion Beam Applications's debt are well covered by earnings due to lack of past financial data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 4.6x debt.


Next Steps

Dividend

What is Ion Beam Applications's current dividend yield, its reliability and sustainability?

1.13%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Unable to evaluate Ion Beam Applications's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Ion Beam Applications's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Ion Beam Applications has not reported any payouts.

Unable to verify if Ion Beam Applications's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Ion Beam Applications has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Ion Beam Applications's salary, the management and board of directors tenure and is there insider trading?

5.3yrs

Average management tenure


CEO

Olivier Legrain (51yo)

7.3yrs

Tenure

€321,458

Compensation

Mr. Olivier Legrain has been the Chief Executive Officer, President and Executive Director at Ion Beam Applications, S.A. since May 9, 2012 and served as its President of Molecular Medicine at Ion Beam App ...


CEO Compensation Analysis

Olivier's remuneration is lower than average for companies of similar size in United States of America.

Olivier's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.3yrs

Average Tenure

53yo

Average Age

The average tenure for the Ion Beam Applications management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

6.7yrs

Average Tenure

57yo

Average Age

The tenure for the Ion Beam Applications board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Pierre Mottet (57yo)

    Chairman of The Board

    • Tenure: 6.3yrs
    • Compensation: €63.75k
  • Yves Jongen (72yo)

    Founder

    • Tenure: 28.3yrs
  • Olivier Legrain (51yo)

    CEO, President

    • Tenure: 7.3yrs
    • Compensation: €321.46k
  • Jean-Marc Bothy (55yo)

    President of IBA Dosimetry

    • Tenure: 1.6yrs
  • Thomas Ralet

    Vice-President of Corporate Communication

    • Tenure: 0yrs
  • Frédéric Nolf (47yo)

    Chief Human Resources & Sustainability Officer

    • Tenure: 9.7yrs
  • Matthias Dierl

    Chief Medical Physicist of Radiation Therapy

    • Tenure: 0yrs
  • Soumya Chandramouli (41yo)

    Chief Financial Officer

    • Tenure: 3.3yrs

Board Members

  • Pierre Mottet (57yo)

    Chairman of The Board

    • Tenure: 6.3yrs
    • Compensation: €63.75k
  • Marcel Miller (66yo)

    Independent Director

    • Tenure: 8.3yrs
    • Compensation: €22.78k
  • Yves Jongen (72yo)

    Founder

    • Tenure: 28.3yrs
  • Eric de Lamotte (62yo)

    Other Director

    • Tenure: 19.6yrs
    • Compensation: €22.78k
  • Olivier Legrain (51yo)

    CEO, President

    • Tenure: 7.3yrs
    • Compensation: €321.46k
  • Jeroen Cammeraat (53yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: €30.94k
  • Katleen Vandeweyer (50yo)

    Independent Director

    • Tenure: 6.7yrs
    • Compensation: €26.86k
  • Sybille Van den Hove (54yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: €23.72k
  • Hedvig Hricak (72yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: €17.68k

Company Information

Ion Beam Applications SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ion Beam Applications SA
  • Ticker: IOBC.F
  • Exchange: OTCPK
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €450.851m
  • Listing Market Cap: €495.822m
  • Shares outstanding: 29.45m
  • Website: https://www.iba-worldwide.com

Number of Employees


Location

  • Ion Beam Applications SA
  • 3, chemin du Cyclotron
  • Louvain-la-Neuve
  • Walloon Brabant
  • 1348
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IOBC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 1998
IBABENXTBR (Euronext Brussels)YesOrdinary SharesBEEURJun 1998
IOBDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 1998
0GZKLSE (London Stock Exchange)YesOrdinary SharesGBEURJun 1998
IBABBBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJun 1998

Biography

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through P ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 23:46
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.